Global healthcare systems are facing critical challenges:

• Longevity gap: Aging population and rising chronic diseases
• Workforce gap: Rising shortage of medical specialists
• Efficiency gap: Increasing healthcare spend 
   

Fresenius is part of the solution: We are actively addressing these global gaps by: 

• driving affordable, innovative medicine and tailored nutrition
• advancing integrated MedTech and digital ecosystems
• strengthening our employer attractiveness! 
   

Our unique strength lies in the strong balance between two system-critical businesses: Fresenius Kabi and Fresenius Helios:

• Fresenius Kabi supplies healthcare products for critically and chronically ill patients (Pharma, Biopharma, Nutrition & MedTech)
• Fresenius Helios is Europe’s leading private hospital operator (Helios Germany & Quirónsalud Spain)

Both businesses hold leading market positions in attractive segments and are set for strong, sustainable organic growth and margin expansion.
 

In October 2022, Fresenius launched its #FutureFresenius strategy. Since then, we have made significant financial and structural progress, making our company more focused, adaptive, and performance driven. 

All key financial metrics in Full-Year 2024 compared to Full-Year 2022 improved – a clear sign that our strategy is working.

Visit our Fresenius Annual Report 2024 for more information.

Persistent macroeconomic volatility and emerging geopolitical tensions, Fresenius delivers consistent performance. This reflects the operating strength and continued execution of #FutureFresenius. While serving global markets, we foster a strong local presence. This way we are able to act quickly – also in uncertainties:

• With our “Local for local” approach, we are closer to our customers. This means: in Europe for Europe, in Asia for Asia, in the U.S. for the U.S.
  
  90% of Group revenues are not exposed to U.S. tariffs, and 70% of total revenues are generated in Europe.
   
• The “More in America” initiative specifically strengthens our strong local presence in U.S. manufacturing.
  
  In recent years, we have invested around 1 billion US dollars in production and logistics in the U.S. Around 70% of the medicines we sell in the U.S. are also manufactured there.

We kicked-off the next phase of #FutureFresenius – Rejuvenate – in 2025: Taking our performance to the next level! 

1. This means upgrading our core businesses by doing what we are doing even better! Through patient care, customer service, better processes and operations, we’re creating value day by day!
    
2. And scaling our three therapy platforms:

• specialized (Bio)Pharma
• targeted MedTech
• holistic Care Provision 

Together they offer strong potential for future growth, innovation and digitalization and thus elevating performance.

Fresenius has transformed into a more focused, performance-driven organization with a strong culture of accountability. Our mission stand firm: to save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.

With over 100 years of experience, Fresenius has grown from a small business into a global healthcare company. Through #FutureFresenius, we’ve become simpler, more adaptive, and more competitive - delivering real impact to patients, caregivers, hospitals, employees, and shareholders alike. We are ready to lead and remain an employer of choice in today’s competitive healthcare landscape.